Increased Expression of Thymidylate Synthetase (TS), Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor Survival in Glioblastoma Multiforme (GBM)

[1]  Martin R. Johnson,et al.  Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. , 2006, The Journal of molecular diagnostics : JMD.

[2]  Martin R. Johnson,et al.  Antitumor Efficacy of Capecitabine and Celecoxib in Irradiated and Lead-Shielded, Contralateral Human BxPC-3 Pancreatic Cancer Xenografts: Clinical Implications of Abscopal Effects , 2005, Clinical Cancer Research.

[3]  P. Deb,et al.  Glioblastoma multiforme with long term survival. , 2005, Neurology India.

[4]  S. Deb,et al.  Intracranial necrotizing granuloma caused by Cladophialophora bantiana. , 2005, Neurology India.

[5]  N. Zaffaroni,et al.  Survivin as a target for new anticancer interventions , 2005, Journal of cellular and molecular medicine.

[6]  René Bernards,et al.  The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. , 2005, Molecular cell.

[7]  Richard Assaker,et al.  Local and Sustained Delivery of 5-Fluorouracil from Biodegradable Microspheres for the Radiosensitization of Malignant Glioma: A Randomized Phase II Trial , 2005, Neurosurgery.

[8]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Judson,et al.  ZD9331: discovery to clinical development , 2005, Anti-cancer drugs.

[10]  A. Amerik,et al.  Mechanism and function of deubiquitinating enzymes. , 2004, Biochimica et biophysica acta.

[11]  S. Fulda,et al.  Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol , 2004, Oncogene.

[12]  S. Rosenfeld,et al.  A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). , 2004, Journal of Clinical Oncology.

[13]  R. Mirimanoff,et al.  Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group , 2004 .

[14]  Susan M. Chang,et al.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. , 2004, Neuro-oncology.

[15]  M. Loda,et al.  The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. , 2004, Cancer cell.

[16]  S. Ashley,et al.  RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine , 2004, Oncogene.

[17]  Tao Zhang,et al.  The Chemopreventive Agent Sulindac Attenuates Expression of the Antiapoptotic Protein Survivin in Colorectal Carcinoma Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  L. Sistonen,et al.  The ubiquitin‐proteasome pathway , 2004, Annals of medicine.

[19]  E. Dees,et al.  The proteasome as a target for cancer therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  D. Altieri.  Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.

[21]  Edward C Halperin,et al.  Is the long‐term survival of patients with intracranial glioblastoma multiforme overstated? , 2003, Cancer.

[22]  David E. Misek,et al.  Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. , 2003, The American journal of pathology.

[23]  Fang Tan,et al.  The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[25]  Edward Chu,et al.  Thymidylate synthase inhibitors as anticancer agents: from bench to bedside , 2003, Cancer Chemotherapy and Pharmacology.

[26]  V. Lam,et al.  GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. , 2003, Cancer research.

[27]  J. Cairncross,et al.  Long‐Term Survivors of Glioblastoma: Statistical Aberration or Important Unrecognized Molecular Subtype? , 2003, Cancer journal.

[28]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[29]  F. Yamasaki,et al.  Expression of survivin in astrocytic tumors , 2003, Cancer.

[30]  G. W. Hatfield,et al.  Differential analysis of DNA microarray gene expression data , 2003, Molecular microbiology.

[31]  Richard Weindruch,et al.  Transcriptional profiles associated with aging and middle age-onset caloric restriction in mouse hearts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Miller,et al.  Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. , 2002, Molecular cancer therapeutics.

[33]  Y. Saga,et al.  Enhanced Expression of Thymidylate Synthase Mediates Resistance of Uterine Cervical Cancer Cells to Radiation , 2002, Oncology.

[34]  M. Nakagawa,et al.  Clinical significance of thymidylate synthase expression in bladder cancer , 2002, International journal of urology : official journal of the Japanese Urological Association.

[35]  Geoffrey J McLachlan,et al.  Selection bias in gene extraction on the basis of microarray gene-expression data , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Martin R. Johnson,et al.  Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. , 2002, Analytical biochemistry.

[37]  J. Qin,et al.  Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization , 2002, Nature.

[38]  J. Hauw,et al.  Long-term survival after gene therapy for a recurrent glioblastoma , 2002, Neurology.

[39]  P. Black,et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Wei Zhang,et al.  Molecular Classification of Human Diffuse Gliomas by Multidimensional Scaling Analysis of Gene Expression Profiles Parallels Morphology‐Based Classification, Correlates with Survival, and Reveals Clinically‐Relevant Novel Glioma Subsets , 2002, Brain pathology.

[41]  N. Tanigawa,et al.  The role of survivin as a new target of diagnosis and treatment in human cancer , 2001, Medical Electron Microscopy.

[42]  R. Vierstra,et al.  The ubiquitin-specific protease UBP14 is essential for early embryo development in Arabidopsis thaliana. , 2001, The Plant journal : for cell and molecular biology.

[43]  Michael L. Wang,et al.  Capecitabine for 5‐Fluorouracil‐Resistant Brain Metastases From Breast Cancer , 2001, American journal of clinical oncology.

[44]  G. Schwartz,et al.  Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[46]  O. Kallioniemi,et al.  Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. , 2000, Cancer research.

[47]  Kangsheng Wang,et al.  Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. , 2000, Analytical biochemistry.

[48]  J. Cairncross,et al.  Which glioblastoma multiforme patient will become a long‐term survivor? A population‐based study , 1999, Annals of neurology.

[49]  T. Tamada,et al.  Thymidylate synthase activity as a prognostic factor in ovarian cancer. , 1994, Oncology.

[50]  T. J. Breen,et al.  Biostatistical Analysis (2nd ed.). , 1986 .

[51]  D. Harrington.  A class of rank test procedures for censored survival data , 1982 .

[52]  R. Fisher.  THE USE OF MULTIPLE MEASUREMENTS IN TAXONOMIC PROBLEMS , 1936 .

[53]  Jim A. Wright,et al.  Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review). , 2003, International journal of oncology.

[54]  K. Aldape,et al.  Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  S. Brem,et al.  Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. , 1998, Journal of neurosurgery.

[56]  M. Fukushima,et al.  A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance , 1998, Cancer.

[57]  M. Aldenderfer,et al.  Cluster Analysis. Sage University Paper Series On Quantitative Applications in the Social Sciences 07-044 , 1984 .